tirzepatide lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity Lilly Shows Tirzepatide Superiority in

Mortality was documented over a period of 14 days

Use restriction For laboratory research use only

Limit alcohol

For compounded semaglutide, such evidence simply does not exist

Consumers with the following priorities may wish to compare this model with traditional in-person care or other treatment pathways: Preference for FDA-approved products exclusively: Consumers who prefer to use only FDA-approved finished products that have undergone the agency's full premarket approval process can access branded GLP-1 medications such as Wegovy or Zepbound through a primary care physician or in-person specialist, where FDA-approved formulations can be prescribed and filled at traditional retail pharmacies